MarketPulse
P

$PFE

95 articles found
53 positive
3 negative
39 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Juvenescence Advances PAI-1 Program With Phase 1 Success, Expands Leadership Team

Juvenescence completes Phase 1 trial of PAI-1 inhibitor MDI-2517 with positive safety results. Company expands leadership and plans Phase 2 study in late 2026.
PFEbiotechclinical development
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly Expands Obesity Drug Lead With Clinical Win and Product Innovation

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.
PFELLYNVOVKTXclinical trialsGLP-1 drugs
BenzingaBenzinga··Vandana Singh

Pfizer's Braftovi Combination Therapy Receives Full FDA Approval for BRAF-Mutated Colorectal Cancer

Pfizer's Braftovi receives full FDA approval for treating BRAF-mutated metastatic colorectal cancer when combined with cetuximab and chemotherapy, based on Phase 3 trial data.
PFEFDA approvalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Bcc Research

Advanced Drug Delivery Systems Market Set to Reach $487B by 2030

Advanced drug delivery systems market projected to grow from $299.6B (2025) to $487.4B (2030), driven by chronic diseases, nanotechnology breakthroughs, and oncology applications.
AMGNBMYCELGrJNJPFE+3personalized medicineAsia-Pacific
GlobeNewswire Inc.GlobeNewswire Inc.··Visiongain

Ophthalmic Drug Market to Reach $41.88B by 2026 Amid Innovation Wave

Global ophthalmic drug market projected to reach $41.88B by 2026, growing 7.9% annually driven by biologic therapies, advanced delivery systems, and AI-enabled diagnostics.
PFEABBVNVSALCRHHBY+3AMDbiologics
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 6.4% Dividend Yield Attracts Income Investors Despite Sector Headwinds

Pfizer's 6.4% dividend yield attracts income investors, but structural challenges like patent expirations and a payout ratio exceeding 100% present execution risks.
PFEdividend yieldincome investing
BenzingaBenzinga··Vandana Singh

BioNTech Sues Moderna Over Patent Rights to Next-Gen COVID Vaccine

BioNTech sues Moderna for patent infringement over next-gen COVID vaccine technology, claiming mNEXSPIKE violates its spike protein patents. Seeking damages for unlicensed use.
PFEMRNABNTXintellectual propertymRNA technology
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Therapeutics Market Poised to Exceed $33B by 2030 on Formulation Innovation

GLP-1 therapeutics market projected to grow from $22B in 2025 to $33B by 2030, driven by formulation innovations like oral and extended-release therapies improving accessibility.
PFELLYNVOAZNpersonalized medicinediabetes treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Sexual Health Supplement Market Set to Expand 40% Through 2030

Sexual health supplement market projected to grow 40% to $5.31 billion by 2030, driven by consumer wellness awareness and demand for natural, personalized products.
PFEGSKmarket growthsexual health supplements
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Turner Syndrome Treatment Market Set to Double by 2033 on Diagnostic Innovation

Turner Syndrome treatment market projected to double to $3.67B by 2033, driven by diagnostic innovation, increased awareness, and improved access to therapies globally.
PFELLYNVSSNYNVO+2healthcarerare disease
BenzingaBenzinga··Vandana Singh

Pfizer's Braftovi Regimen Achieves Primary Endpoints in Metastatic Colorectal Cancer Trial

Pfizer's Braftovi regimen met primary endpoints in Phase 3 colorectal cancer trial, showing significant improvements in progression-free survival versus standard chemotherapy in BRAF-mutated patients.
PFEFDLPJPcolorectal cancerBraftovi
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider Research

Fibrin Sealant Market Poised to Double to $3.57B by 2035 Amid Surgical Demand

Fibrin sealant market to double from $1.60B to $3.57B by 2035, driven by surgical demand and minimally invasive techniques despite accessibility challenges in developing regions.
JNJPFESYKMDTBAX+1market growthminimally invasive surgery
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider Research

Uterine Fibroid Treatment Market Poised for 7.63% Annual Growth Through 2033

Global uterine fibroid treatment market projected to grow 7.63% annually through 2033, reaching $9.43 billion. Growth driven by high disease prevalence and minimally invasive surgical advances.
JNJPFEABBVSYKMDT+9market growthminimally invasive procedures
The Motley FoolThe Motley Fool··Matthew Benjamin

Eli Lilly Positions Itself as Pharma Leader Through GLP-1 Dominance and Strategic M&A

Eli Lilly strengthens market position through GLP-1 dominance and strategic acquisitions like Orna Therapeutics, diversifying growth beyond patent cliff risks.
PFELLYacquisitionsgene therapy
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 6.3% Yield Hinges on GLP-1 Drug Data, Patent Cliff Challenges

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.
PFELLYNVOdividend yieldclinical trial results